lenacapavir reduced HIV infections by 96% ... The most common side effect was the formation of harmless subcutaneous nodules, which typically decreased with subsequent injections.

The widespread utilization of chest CT scans has increased the importance of the proper evaluation of incidentally found lung nodules. The primary goal in the evaluation of these nodules is to ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

A solitary pulmonary nodule (SPN) is an isolated lung growth surrounded by normal tissue. Most SPNs are benign (not cancerous) when they're diagnosed. However, some nodules can enlarge and change over ...

In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...

Kisii — The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA ...

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

US pharma company Gilead Sciences is seeking regulatory approval for the drug lenacapavir in a number of African countries – a key step towards making it available across the region, where ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.

But will doctors use it? In its push to gain approval for its long-acting answer lenacapavir, Gilead also has reported stellar results from two phase 3 trials including the PURPOSE 1 study ...

Gilead Sciences has as of late been locked in on its bread-and-butter antiviral franchise with an eye on the potential of its long-acting HIV med lenacapavir. But with its cell therapy unit ...